Recent Literature on Clonidine in Children and Adolescents
Conidine was approved as an antihypertensive medication by the Food and Drug Administration (FDA) in 1974, but it soon became adopted for other uses, including management of attention deficit/hyperactivity disorder (ADHD). It wasn't until the review of a new extended release formulation (Kapvay®) in October 2010 that the FDA approved clonidine for the treatment of ADHD as monotherapy or as adjunctive to stimulant medication. In addition to this use, clonidine has played a role in a wide variety of conditions, including sleep disturbances, headaches, agitation following traumatic brain injury, and postoperative nausea and vomiting. This issue will review a selection of papers published in the last three years that suggest a growing role for clonidine in pediatric patients.
Abstract
Conidine was approved as an antihypertensive medication by the Food and Drug Administration (FDA) in 1974, but it soon became adopted for other uses, including management of attention deficit/hyperactivity disorder (ADHD). It wasn't until the review of a new extended release formulation (Kapvay®) in October 2010 that the FDA approved clonidine for the treatment of ADHD as monotherapy or as adjunctive to stimulant medication. In addition to this use, clonidine has played a role in a wide variety of conditions, including sleep disturbances, headaches, agitation following traumatic brain injury, and postoperative nausea and vomiting. This issue will review a selection of papers published in the last three years that suggest a growing role for clonidine in pediatric patients.
Source...